CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that based on recommendations from the Compensation Committee
of the Company's Board of Directors, on June 7, 2017, the Company's
Board of Directors approved the grants of inducement stock options to
purchase a total of 325,000 shares of the common stock to two new
employees, with a grant date of June 15, 2017 (the "Inducement Grants").
The Inducement Grants include a stock option grant to Ralf Rosskamp,
M.D., to purchase 250,000 shares of common stock. Dr. Rosskamp joined
the Company as chief medical officer on June 14, 2017.
The Inducement Grants were granted pursuant to Dicerna's 2016 Inducement
Plan and will have an exercise price per share equal to the fair market
value of our common stock on the grant date. The stock options vest over
four years, with 25% vesting on the one-year anniversary of the
employee's first day of employment with the Company and 1/36 of the
remaining shares vesting monthly thereafter, subject to the new
employee's continued service relationship with the Company on each such
date. Each stock option has a 10-year term and is subject to the terms
and conditions of the applicable stock option agreement.
The stock options were granted as an inducement material to the new
employees entering into employment with Dicerna Pharmaceuticals, Inc. in
accordance with NASDAQ Listing Rule 5635(c)(4).
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the discovery and development of innovative ribonucleic acid
interference (RNAi)-based therapeutics for diseases involving the liver,
including rare diseases, chronic liver diseases, cardiovascular
diseases, and viral infectious diseases. The Company is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad pipeline in
these core therapeutic areas, focusing on target genes where connections
between target gene and diseases are well understood and documented. The
Company intends to discover, develop and commercialize novel
therapeutics either on its own or in collaboration with pharmaceutical
partners. For more information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Applicable risks and uncertainties include
those relating to our preclinical research and other risks identified
under the heading "Risk Factors" included in our most recent Form 10-Q
filing and in other future filings with the SEC. The forward-looking
statements contained in this press release reflect Dicerna's current
views with respect to future events, and Dicerna does not undertake and
specifically disclaims any obligation to update any forward-looking
View source version on businesswire.com: http://www.businesswire.com/news/home/20170615005169/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media